Decrease in vRNA in brain during antiretroviral therapy. by Sonny R. Elizaldi (9684796)

This is the raw data of Immunofluorescence in Met-5A cell. by Yangyang Yin (14323701)

Subjects:

Decrease in circulating iNKT cell activation during regadenoson (RA) infusion into patients with COVID-19. by Joseph Rabin (7399436)

Subjects:

This is the raw data of Western blot in Met-5A cell. by Yangyang Yin (14323701)

Subjects:

Body and absolute and relative organ weights of rats post PM2.5 exposure (‾χ±s, n =  8). by Cao Wang (1500691)

Subjects:

Comparison of the decrease of CFU in CSF and blood between treatment groups within the first 6 h after treatment. by Luca G. Valente (12463057)

Fig 5 - by Andrea R. Thurman (5286005)

Transcriptional and translational markers of syncytialization and biochemical differentiation are significantly decreased by rotenone. by O’Llenecia S. Walker (8486163)

MiR-132-3p was downregulated in TGF-<i>β</i>1 stimulated Met-5A cells and miR-132-3p mimics and miR-132-3p inhibitor transfected Met-5A cells. by Yangyang Yin (14323701)

Subjects:

This is the raw data of IHC-1 in Rat. by Yangyang Yin (14323701)

Subjects:

Sequences of the primers for q-PCR. by Yangyang Yin (14323701)

Subjects:

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

Subjects:

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

Subjects:

Trial profile. by Chanel Avenant (409756)

“…Both contraceptives substantially decreased, from D0 to 25W, the total testosterone [DMPA-IM D0 0.560, 25W 0.423 nmol/L, -24.3% (p < 0.0001); NET-EN D0 0.551, 25W 0.253 nmol/L, -54.1%, (p < 0.0001)], SHBG [DMPA-IM D0 45.0, 25W 32.7 nmol/L, -29.8% (p < 0.0001); NET-EN D0 50.2, 25W 17.6 nmol/L, -65.1% (p < 0.0001)], and calculated free testosterone levels [DMPA-IM D0 6.87, 25W 5.38 pmol/L, -17.2% (p = 0.0371); NET-EN D0 6.00, 25W 3.70, -40.0% (p < 0.0001)]. …”

Flowchart of study selection. by Alejandro Piscoya (782326)

Subjects:

Description of characteristics of included studies. by Alejandro Piscoya (782326)

Subjects:

Effect of remdesivir on invasive ventilation at 14 days. by Alejandro Piscoya (782326)

Subjects:

Effect of remdesivir on all-cause mortality at 14 days. by Alejandro Piscoya (782326)

Subjects:

Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

Subjects:

Summary of findings table for the comparison remdesivir 5 days vs. standard of care for hospitalized, moderate COVID-19. by Alejandro Piscoya (782326)

Subjects: